Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Increase kidney function monitoring if INR exceeds 4.0

Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

Key clinical point: More frequent monitoring of kidney function might be considered for patients on warfarin with an INR of 4.0 or greater.

Major finding: Among patients with warfarin anticoagulation, 13% had an acute kidney injury.

Study details: A retrospective study of 292 patients with an INR of 4.0 or greater who were treated between 2007 and 2017.

Disclosures: Dr. Traquair reported having no financial disclosures.

Source: Traquair H et al. THSNA 2018, Poster 79.

Citation:

Traquair H et al. biennial summit of the Thrombosis & Hemostasis Societies of North America 2018, Poster 79.

This Week's Must Reads

Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30

Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331

Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919

T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51

Must Reads in Bleeding Disorders

Laced synthetic cannabinoid leads to bleeding, Kelkar AH et al. N Engl J Med. 2018;379:1216-23.

Phase 3 data on emicizumab, Mahlangu et al. N Engl J Med. 2018;379:811-22

Integrated programs ease sickle cell pain, hospitalizations, Annual meeting of the Foundation for Sickle Cell Disease Research

Watch for RBC adhesion in men with sickle cell , Annual meeting of the Foundation for Sickle Cell Disease Research

FDA approves Jivi for hemophilia A, Package insert, news release